-
公开(公告)号：WO2018178392A1
公开(公告)日：2018-10-04
申请号：PCT/EP2018/058448
申请日：2018-04-03
Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventor： FELDWISCH, Joachim , LINDBORG, Malin , NILSSON, Joakim , NORDLING, Erik , SVENSSON, Robert
Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif ( BM ) EX 2 X 3 X 4 X 5 X 6 X 7 EIX 10 X 11 LPNLX 16 RX 18 QYX 21 AFIX 25 X 26 LX 28 D. The present disclosure also relates to the use of such an IL-1R-I binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.
-
公开(公告)号：WO2015150490A1
公开(公告)日：2015-10-08
申请号：PCT/EP2015/057256
申请日：2015-04-01
Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventor： BERGHARD, Charlotta , NORDLING, Erik , SVENSSON GELIUS, Stefan , TJERNBERG, Agneta
IPC: C07K14/435
CPC classification number: C12N9/14 , A61K38/00 , C12N9/96 , C12Y310/01001
Abstract: Disclosed herein are a modified sulfamidase, a composition comprising a modified sulfamidase, as well as methods for preparing a modified sulfamidase and therapeutic use of such a sulfamidase. In particular, the present disclosure relates to a modified sulfamidase comprising substantially no epitopes for glycan recognition receptors, thereby enabling transportation of said sulfamidase across the blood brain barrier of a mammal, wherein said sulfamidase has catalytic activity in the brain of said mammal.
Abstract translation: 本文公开了改性的磺酰胺酶，包含改性的磺酰胺酶的组合物，以及制备修饰的磺酰胺酶的方法和这种磺酰胺酶的治疗用途。 具体地说，本公开内容涉及基本上不含聚糖识别受体的表位的修饰的磺酰胺酶，从而使所述磺酰胺酶能够跨越哺乳动物的血脑屏障传递，其中所述的磺酰胺酶在所述哺乳动物的脑中具有催化活性。
-
公开(公告)号：WO2019201866A1
公开(公告)日：2019-10-24
申请号：PCT/EP2019/059692
申请日：2019-04-15
Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventor： JAMES, Stephen , KAISER, Christina , NILSSON, Joakim , NORDLING, Erik , STRÖMBERG, Patrik , SVENSSON GELIUS, Stefan , LETHAGEN, Stefan , CORNVIK, Tobias , SVENSSON, Robert
Abstract: A fusion protein is provided, comprising an antibody fragment having a biologic activity, said antibody fragment being selected from the group consisting of a Fab, a ScFv, a dAb, a VHH and a VNAR; and one or more half-life extending polypeptide moieties, each moiety comprising 2 to 136 units, with the proviso that said moiety or multiple moieties in total comprises 10 to 136 units, wherein each unit is independently selected from the group consisting of all amino acid sequences according to SEQ ID NO:1: X1-X2-X3-X4-X5-X6-D-X8-X9-X10-X11 (SEQ ID NO: 1) in which, independently: X1 is P or absent; X2 is V or absent; X3 is P or T; X4 is P or T; X5 is T or V; X6 is D, G or T; X8 is A, Q or S; X9 is E, G or K; X10 is A, E P or T; and X11 is A, P or T. The half-life extending polypeptide moiety has a generally unfolded conformation and provides a fusion protein with a large hydrodynamic radius that may avoid renal clearance. As a result, the biological half-life of the fusion protein is increased and the biological effect of the biologically active polypeptide may thus be prolonged.
-
公开(公告)号：WO2019201855A1
公开(公告)日：2019-10-24
申请号：PCT/EP2019/059675
申请日：2019-04-15
Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventor： NILSSON, Joakim , NORDLING, Erik , SANDEGREN, Anna , SVENSSON GELIUS, Stefan , POSSNER, Dominik
Abstract: A fusion protein is disclosed, comprising (i) a lysosomal polypeptide; and (ii) a polypeptide moiety comprising 2-68 units, each unit being independently selected from the group consisting of all amino acid sequences according to SEQ ID NO: 1 : in which, independently: X1 is P or absent; X2 is V or absent; X3 is P or T; X4 is P or T; X5 is T or V; X6 is D, G or T; X8 is A, Q or S; X9 is E, G or K; X10 is A, E P or T; and X11 is A, P or T. The fusion protein exhibits improved distribution to target tissue and is useful in enzyme replacement therapy of lysosomal storage disease.
-
Patent Agency Ranking
公开(公告)号：WO2015028558A1
公开(公告)日：2015-03-05
申请号：PCT/EP2014/068282
申请日：2014-08-28
Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventor： NILSSON, Joakim , NORDLING, Erik , STRÖMBERG, Patrik
CPC classification number: C07K14/47 , A61K38/00 , C07K14/315
Abstract: The invention relates to a polypeptide capable of binding human complement component 5 (C5), said polypeptide comprising the amino acid sequence [ BM ]-[L2]-QSX 42 X 43 LLX 46 EAKKLX 52 X 53 X 54 Q wherein [ BM ] is a C5 bindingmotif; [L2] is an interconnecting loop; X 42 is selected from A and S; X 43 is selected from N and E; X 46 is selected from A, S and C; X 52 is selected from E, N and S; X 53 is selected from D, E and S, provided that X 53 is not D when X 52 is N; and X 54 is selected from A and S.
Abstract translation: 本发明涉及能够结合人补体成分5（C5）的多肽，所述多肽包含氨基酸序列[BM] - [L2] -QSX42X43LLX46EAKKLX52X53X54Q，其中[BM]是C5结合蛋白; [L2]是互连环路; X42选自A和S; X43选自N和E; X46选自A，S和C; X52选自E，N和S; X53选自D，E和S，条件是当X52为N时，X53不为D; X54选自A和S.
-
公开(公告)号：WO2017055570A1
公开(公告)日：2017-04-06
申请号：PCT/EP2016/073452
申请日：2016-09-30
Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventor： NORDLING, Erik , STRÖMBERG, Patrik , SVENSSON GELIUS, Stefan
CPC classification number: C12N9/14 , A61K38/00 , C12Y301/06013 , C12Y302/01076 , C12Y310/01001
Abstract: Disclosed herein are a modified lysosomal protein, methods for preparing a modified lysosomal protein and therapeutic use of such a modified protein. Further disclosed herein is a method of treating a mammal afflicted with a lysosomal storage disease.In particular, the present disclosure relates to a method of preparing a modified lysosomal protein, said method comprising reacting a glycosylated lysosomal protein with an alkali metal periodate and reacting said lysosomal protein with an alkali metal borohydride for a time period of no more than 2 h, thereby modifying glycan moieties of the lysosomal protein and reducing the activity of the lysosomal protein with respect to glycan recognition receptors.
Abstract translation: 本文公开了修饰的溶酶体蛋白质，制备修饰的溶酶体蛋白质的方法和这种修饰蛋白质的治疗用途。 本文进一步公开的是治疗患有溶酶体贮积病的哺乳动物的方法。特别地，本公开内容涉及制备修饰的溶酶体蛋白的方法，所述方法包括使糖基化溶酶体蛋白与碱金属高碘酸酯反应并使所述 溶酶体蛋白与碱金属硼氢化物的时间不超过2小时，从而修饰溶酶体蛋白的聚糖部分并降低溶酶体蛋白质相对于聚糖识别受体的活性。
-
公开(公告)号：WO2019201868A1
公开(公告)日：2019-10-24
申请号：PCT/EP2019/059695
申请日：2019-04-15
Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventor： CORNVIK, Tobias , NILSSON, Joakim , NORDLING, Erik , SVENSSON GELIUS, Stefan
IPC: A61K38/36 , C12N9/64 , C07K14/745 , C07K14/47 , A61K38/00
Abstract: A fusion protein is provided, comprising i) a coagulation factor protein selected from coagulation factor X (FX), coagulation factor IX (FIX) and variants thereof; and ii) a half-life extending polypeptide moiety comprising 2-80 units independently selected the amino acid sequences according to SEQ ID NO: 1: in which, independently: X1 is P or absent; X2 is V or absent; X3 is P or T; X4 is P or T; X5 is T or V; X6 is D, G or T; X8 is A, Q or S; X9 is E, G or K; X10 is A, E P or T; and X11 is A, P or T. The half-life extending polypeptide moiety has a generally unfolded conformation and provides a fusion protein with a large hydrodynamic radius that may avoid renal clearance. As a result, the biological half-life of the fusion protein is increased and the biological effect of the FX or FIX may thus be prolonged.
-
公开(公告)号：WO2018233895A1
公开(公告)日：2018-12-27
申请号：PCT/EP2018/059677
申请日：2018-04-16
Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventor： NILSSON, Joakim , NORDLING, Erik , SVENSSON GELIUS, Stefan
IPC: C12N9/20
Abstract: A fusion protein is provided, comprising i) a biologically active polypeptide; and ii) a half-life extending polypeptide moiety comprising 2-80 units independently selected the amino acid sequences according to SEQ ID NO: 1: X1-X2-X3-X4-X5-X6-D-X8-X9-X10-X11 (SEQ ID NO: 1) in which, independently: X1 is P or absent; X2 is V or absent; X3 is P or T; X4 is P or T; X5 is T or V; X6 is D, G or T; X8 is A, Q or S; X9 is E, G or K; X10 is A, E P or T; and X11 is A, P or T. The half-life extending polypeptide moiety has a generally unfolded conformation and provides a fusion protein with a large hydrodynamic radius that may avoid renal clearance. As a result, the biological half-life of the fusion protein is increased and the biological effect of the biologically active polypeptide may thus be prolonged.
-
公开(公告)号：WO2017055586A1
公开(公告)日：2017-04-06
申请号：PCT/EP2016/073476
申请日：2016-09-30
Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Inventor： NORDLING, Erik , STRÖMBERG, Patrik , SVENSSON GELIUS, Stefan
CPC classification number: C12Y301/06013 , A61K38/00 , C12N9/16
Abstract: Disclosed herein are a modified iduronate 2-sulfatase, a composition comprising a modified iduronate 2-sulfatase, as well as methods for preparing a modified iduronate 2-sulfatase and therapeutic use of such a iduronate 2-sulfatase. In particular, the present disclosure relates to a modified iduronate 2-sulfatase sulfatase comprising substantially no epitopes for glycan recognition receptors, wherein said iduronate 2-sulfatase has a catalytic activity of at least 50 % of that of unmodified iduronate 2-sulfatase in vitro.
Abstract translation: 本文公开了改性的阿片糖酸2-硫酸酯酶，包含改性的阿魏酸2-硫酸酯酶的组合物，以及制备改性的阿魏酸2-硫酸酯酶的方法和这种艾杜糖醛酸2-硫酸酯酶的治疗用途。 特别地，本公开内容涉及基本上不含聚糖识别受体的表位的改性的阿片糖异构体2-硫酸酯酶硫酸酯酶，其中所述伊曲糖酸2-硫酸酯酶的体外催化活性至少为未修饰的阿魏酸2-硫酸酯酶的50％。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.019 seconds)
